Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level

Daniela I. Batovska; Dong Hoon Kim; Shinya Mitsuhashi; Yoon Sun Cho; Ho Jeong Kwon; Makoto Ubukata

doi:10.1271/bbb.80303

Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level

Daniela I. Batovska, Dong Hoon Kim, Shinya Mitsuhashi, Yoon Sun Cho, Ho Jeong Kwon, Makoto Ubukata

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC₅₀ values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.

Original language	English
Pages (from-to)	2623-2631
Number of pages	9
Journal	Bioscience, Biotechnology and Biochemistry
Volume	72
Issue number	10
DOIs	https://doi.org/10.1271/bbb.80303
Publication status	Published - 2008

Bibliographical note

Funding Information:
We are grateful to Dr. Stuart Schreiber for presenting histacin and tubacin. This study was supported in part by grant-in-aid for Scientific Research (A) (no. 19208011), and for Scientific Research on Priority Area ‘‘Creation of Biologically Functional Molecules’’ from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MU), and by grant-in-aid for the National R & D Program for Cancer Control from the Ministry of Health & Welfare (0620360-1) and for the Brain Korea 21 Project, Republic of Korea (HJK). DIB and SM were supported by postdoctoral fellowships from the Japan Society for the Promotion of Science.

All Science Journal Classification (ASJC) codes

Biotechnology
Analytical Chemistry
Biochemistry
Applied Microbiology and Biotechnology
Molecular Biology
Organic Chemistry

Access to Document

10.1271/bbb.80303

Cite this

@article{9dda16b4e1a54a0f841f1b96b11d94b4,

title = "Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level",

abstract = "Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.",

author = "Batovska, {Daniela I.} and Kim, {Dong Hoon} and Shinya Mitsuhashi and Cho, {Yoon Sun} and Kwon, {Ho Jeong} and Makoto Ubukata",

note = "Funding Information: We are grateful to Dr. Stuart Schreiber for presenting histacin and tubacin. This study was supported in part by grant-in-aid for Scientific Research (A) (no. 19208011), and for Scientific Research on Priority Area {\textquoteleft}{\textquoteleft}Creation of Biologically Functional Molecules{\textquoteright}{\textquoteright} from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MU), and by grant-in-aid for the National R & D Program for Cancer Control from the Ministry of Health & Welfare (0620360-1) and for the Brain Korea 21 Project, Republic of Korea (HJK). DIB and SM were supported by postdoctoral fellowships from the Japan Society for the Promotion of Science.",

year = "2008",

doi = "10.1271/bbb.80303",

language = "English",

volume = "72",

pages = "2623--2631",

journal = "Bioscience, Biotechnology and Biochemistry",

issn = "0916-8451",

publisher = "Japan Society for Bioscience Biotechnology and Agrochemistry",

number = "10",

}

TY - JOUR

T1 - Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level

AU - Batovska, Daniela I.

AU - Kim, Dong Hoon

AU - Mitsuhashi, Shinya

AU - Cho, Yoon Sun

AU - Kwon, Ho Jeong

AU - Ubukata, Makoto

N1 - Funding Information: We are grateful to Dr. Stuart Schreiber for presenting histacin and tubacin. This study was supported in part by grant-in-aid for Scientific Research (A) (no. 19208011), and for Scientific Research on Priority Area ‘‘Creation of Biologically Functional Molecules’’ from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MU), and by grant-in-aid for the National R & D Program for Cancer Control from the Ministry of Health & Welfare (0620360-1) and for the Brain Korea 21 Project, Republic of Korea (HJK). DIB and SM were supported by postdoctoral fellowships from the Japan Society for the Promotion of Science.

PY - 2008

Y1 - 2008

N2 - Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.

AB - Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.

UR - http://www.scopus.com/inward/record.url?scp=55049101683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049101683&partnerID=8YFLogxK

U2 - 10.1271/bbb.80303

DO - 10.1271/bbb.80303

M3 - Article

C2 - 18838793

AN - SCOPUS:55049101683

VL - 72

SP - 2623

EP - 2631

JO - Bioscience, Biotechnology and Biochemistry

JF - Bioscience, Biotechnology and Biochemistry

SN - 0916-8451

IS - 10

ER -

Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this